Recently, the World Health Organization (WHO) officially released the "Global Tuberculosis Report 2025", as the primary cause of death of a single infectious agent, tuberculosis continues to threaten global public health, and its burden is particularly heavy in regions with low levels of economic development.

global data overview

According to the report, there will be an estimated 10.7 million new cases of tuberculosis worldwide in 2024, and the number of deaths due to tuberculosis will be as high as 1.23 million. Although the number of new cases and deaths worldwide in 2024 decreased slightly compared to 2023 (down about 1% and 2%, respectively), there were about 390,000 new cases of multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB), also down 2.5% from last year. However, in the long run, global prevention and control progress is still lagging behind, far from the 2025 milestone set by the WHO "Strategy to End Tuberculosis".

Domestic situation: The road is long and difficult, and the journey is coming

In recent years, the state has continued to increase its support for tuberculosis prevention and control, and promoted the systematic transformation of prevention and control strategies from "passive testing" to "active screening" through the two-wheel drive of policy guidance and financial guarantees. The screening pilots laid out nationwide have provided practical basis and standardized guidance for screening methods and models, promoted the continuous systematization and maturity of screening work, and have achieved phased results.

On this basis, the grassroots drug resistance detection capacity building project has been effectively implemented, giving full play to the role of grassroots designated medical institutions, significantly improving the early screening ability and diagnostic efficiency of drug-resistant tuberculosis, and effectively reducing the diagnosis delay of patients. At the same time, publicity and education efforts have continued to increase, and by mobilizing the participation of the whole people, we will comprehensively enhance the public's awareness of prevention and control, form a joint force of social co-governance, and jointly help accelerate the process of tuberculosis prevention and control in an all-round way.

With the support of a series of policies, China's tuberculosis prevention and control system has been continuously improved, and the prevention and control work has been steadily advancing, and the overall results are gradually emerging.

< The incidence of br/>

has decreased significantly: In 2024, the estimated number of new tuberculosis patients in China will be 696,000, with an incidence rate of 49/100,000, a decrease of 5.8% compared with 2023, and the total incidence of tuberculosis in China will decrease by 24% between 2015 and 2024. Ranking among countries with a high burden of TB dropped from 3rd to 4th.

Effective control of deaths: the estimated number of tuberculosis deaths is 25,000, and the mortality rate is 1.7/100,000.From 2015 to 2024, the total number of tuberculosis deaths in China has decreased by 34%, with remarkable results.

The capacity of the prevention and control system has been improved: China's rapid diagnosis coverage rate has reached 87%, and the positive etiological rate in confirmed tuberculosis accounts for 73%. The proportion of patients diagnosed with bacteriology who are tested for rifampicin resistance is as high as 91%.

Challenges that cannot be ignored:

At present, China's tuberculosis prevention and control is still facing severe challenges. Despite the continuous decline in the incidence, China is still one of the countries with a high burden of tuberculosis in the world. Of particular note is that the estimated number of new MDR/rifampicin-resistant TB patients is still 28,000, highlighting the importance of drug-resistant TB prevention and control. This situation also clearly reminds us that we must accelerate the further sinking and popularization of precision diagnosis technology to primary medical institutions to build a key line of defense for the prevention and treatment of drug-resistant tuberculosis.

Rocgene

TB Solution

Rocgene has successfully developed three detection reagents: iFIND TBR, IFQ and NTM based on the iFIND automatic molecular nucleic acid detection platform. This series of products can directly detect raw samples such as sputum, realize the identification and classification of mycobacterium tuberculosis and non-tuberculous mycobacteria, and simultaneously detect the resistance of core anti-tuberculosis drugs such as rifampicin, isoniazid and fluoroquinolones. At present, TBR Mycobacterium tuberculosis identification and rifampicin resistance detection reagents have been officially approved for marketing, and IFQ and NTM reagents are also in the registration and application stage. The three reagents are applied in tandem to comprehensively cover key links such as tuberculosis screening, typing and drug resistance testing, providing systematic technical support for precise prevention and control and individualized treatment of tuberculosis.

iFIND TBR detection reagent

● Detection target: Mycobacterium tuberculosis identification, rifampicin resistance-related genes

● Functional characteristics: It has high detection sensitivity, effectively improves the positive detection rate of etiology, helps early screening and diagnosis of tuberculosis, and covers key drug resistance sites based on molecular beacon melting curve technology, with high drug resistance detection accuracy

of

iFIND IFQ detection reagent

● Detection target: isoniazid, fluoroquinolone resistance-related genes

● Functional characteristics: covering core first- and second-line anti-tuberculosis drugs, providing a key basis for the accurate diagnosis and treatment of drug-resistant tuberculosis, realizing individualized medication guidance, and improving the success rate of treatment

iFIND NTM detection reagent

● Detection targets: Mycobacterium tuberculosis complex group and 7 common non-tuberculous mycobacteria (bird, intracellular, turtle, abscess, Kansas, occasional, Mycobacterium gordon

● Functional characteristics: accurately distinguish between tuberculosis and non-tuberculous mycobacteria, and accurately type non-tuberculous mycobacteria, providing an important basis for the differential diagnosis and treatment strategy formulation of mycobacterial infection.Advancing Precision Medicine Practices

iFIND Ordering Information List